Evidence map›Paper›PMID 29247525›Full record

ArticleClinical cardiology2017

QTc dispersion and Cornell duration product can predict 10-year outcomes in hypertensive patients with left ventricular hypertrophy.

Dragan B Djordjević, Ivan S Tasić, Svetlana I Kostić, Bojana N Stamenković, Aleksandar D Djordjević, Dragan B Lović

Abstract readComparative Study
In one paragraph

Article in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dragan B DjordjevićMedical Faculty, Department of Internal Medicine, University of Niš, Niš, Serbia.
Ivan S TasićMedical Faculty, Department of Internal Medicine, University of Niš, Niš, Serbia.
Svetlana I KostićDepartment of Cardiology, Institute for Treatment and Rehabilitation Niška Banja, Niš, Serbia.
Bojana N StamenkovićMedical Faculty, Department of Internal Medicine, University of Niš, Niš, Serbia.
Aleksandar D DjordjevićMedical Faculty, University of Niš, Niš, Serbia.
Dragan B LovićDepartment of Cardiology, Clinic for Internal Diseases Intermedica, Niš, Serbia; and Veterans Affairs Medical Center, Washington, District of Columbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersistent and adequate treatment of patients with arterial hypertension leads to more favorable disease outcome. HYPOTHESIS: Aside for the present left ventricular hypertrophy (LVH), there are other non-invasive parameters which can represent additional predictors of unfavorable prognosis in patients with essential arterial hypertension during the 10-year follow-up.

methodsA hypertensive group with LVH (124 patients; age 57.0 ± 8.0; 84 males and 40 females) was included in the study and examined noninvasively. Patients used regular medication therapy during the follow-up period.

resultsDuring the 10-year follow-up period, unfavorable outcome was recorded for 40 (32.3%) patients. Patients with unfavorable outcome had higher baseline values of left ventricular mass index (178.9 ± 29.5 g/m

conclusionsPatients with a positive Cornell product and larger QTc dispersion had more unfavorable 10-year outcomes compared with other patients with LVH.

Indexed as

Cornell Medical IndexElectrocardiography, AmbulatoryForecastingBlood PressureBlood Pressure Monitoring, AmbulatoryEchocardiographyFemaleFollow-Up StudiesHeart VentriclesHumansHypertensionHypertrophy, Left VentricularIncidenceMaleMiddle AgedOutpatient Clinics, HospitalCardiac HypertrophyEchocardiographyElectrocardiographyHypertension

Identifiers

PMID29247525
PMCPMC6490563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.